

GLAXOSMITHKLINE PLC

Form 6-K

January 11, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 11 January 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc(the'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.2440	8 (partnership shares)
£15.2440	8 (matching shares)

Aggregated information

- d) Aggregated volume 16 Ordinary Shares  
Price £15.2440
- e) Date of the transaction 2019-01-10
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Vaccines
  - c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Ordinary shares of 25 pence each  
(‘Ordinary Shares’)

ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)  
£15.2440 8 (partnership shares)  
£15.2440 8 (matching shares)
- Aggregated information
- d) Aggregated volume 16 Ordinary Shares  
Price £15.2440
- e) Date of the transaction 2019-01-10
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
- b) Position/status Chief Financial Officer
- c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each  
(‘Ordinary Shares’)

ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)  
£15.2440 8 (partnership shares)  
£15.2440 8 (matching shares)

Aggregated information

- d) Aggregated volume 16 Ordinary Shares  
Price £15.2440
- e) Date of the transaction 2019-01-10

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons  
 b) Position/status SVP, Global Ethics & Compliance  
 c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument  
 ISIN: GB0009252882

b) Nature of the transaction  
 Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £15.2440 8 (partnership shares)  
 £15.2440 8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares  
 Price £15.2440

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Miels  
 b) Position/status President, Global Pharmaceuticals  
 c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s) Price(s) Volume(s)  
 £15.2440 8 (partnership shares)  
 £15.2440 8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares  
 Price £15.2440

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

b) Position/status Chief Strategy Officer

c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s) Price(s) Volume(s)  
 £15.2440 8 (partnership shares)  
 £15.2440 8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares  
 Price £15.2440

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R Simard

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status President, Pharma Supply Chain
- c) Initial notification/amendment Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
- 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument  
ISIN: GB0009252882

- b) Nature of the transaction  
Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)  
Price(s) Volume(s)  
£15.2440 8 (partnership shares)  
£15.2440 8 (matching shares)

Aggregated information

- d) Aggregated volume  
Price  
16 Ordinary Shares  
£15.2440
- e) Date of the transaction  
2019-01-10
- f) Place of the transaction  
London Stock Exchange (XLON)

- 1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/amendment Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
- 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument  
ISIN: GB0009252882

- b) Nature of the transaction  
Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)  
Price(s) Volume(s)  
£15.2440 8 (partnership shares)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£15.2440 8 (matching shares)

Aggregated information

- d) Aggregated volume 16 Ordinary Shares  
Price £15.2440
- e) Date of the transaction 2019-01-10
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson
- b) Position/status President, Global Affairs
- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

- c) Price(s) and volume(s)  
Price(s) Volume(s)  
£15.2440 8 (partnership shares)  
£15.2440 8 (matching shares)

Aggregated information

- d) Aggregated volume 16 Ordinary Shares  
Price £15.2440
- e) Date of the transaction 2019-01-10
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £15.2440 8 (partnership shares) £15.2440 8 (matching shares)
Aggregated information	
d) Aggregated volume	16 Ordinary Shares
Price	£15.2440
e) Date of the transaction	2019-01-10
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 11, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc